|
BioImagene India Pvt. Ltd launches
its new facility
-Launched by Dr. R. A Mashelkar, DG, CSIR-
Pune, India: Thursday,
20th October, 2005: BioImagene India
Pvt. Ltd. a 100% subsidiary of BioImagene Inc.
California (USA) launched its new premises
at Godrej Eternia today. The
official launch was done by Dr. R.A. Mashelkar,
Director General, CSIR in the presence of Padmashree
Lila Poonawalla, Advisory Board Member, BioImagene,
and other industry veterans.
Since its inception in 2003, BioImagene
has been completely on the growing curve. From
3 people, in the initial stages, it is now a strong
team of 65 BIO-IT specialists. BioImagene today,
is pioneering a new generation of life science
Image Informatics solutions catering to the specific
needs of research scientists and pathologists world
over. In this short span, they have a prominent
client portfolio, which reads almost like who’s
who of the worlds top Pharma companies. Pharma
giants like Eli Lilly, Pfizer, Merck, and Roche
to name just a few as customers and research collaborations
with prominent Universities, is a clear indication
that they are a company, which is committed to
Life Science research and development. BioImagene
today has a strong IP portfolio too with 10 patents
and 2 patent applications.
BioImagene is also working for
esteemed customers like PHC Labs in Hong Kong,
UC Davis at California, Bartes Hospital at UK,
US Labs and Allergan LLC at Southern California
to name a few.
Speaking of this occasion
Dr. Mashelkar said, “BioImagene
can become the provider of world-class solutions
to the whole world in paramedics and diagnostics,
solutions that will benefit both India and the
World”. In the entire process of drug discovery,
development, delivery, the key is that the drug
should be affordable, available, and accessible
to all, and what BioImagene is doing in this
context is extraordinarily important. “We
feel that bioinformatics is a tool for pharmaco-chemistry,
and what you have added is a new tool to that
armory. BioImagene is setting the world on fire”,
Dr. Mashelkar further added.
Expressing his views Abhijeet
Gholap, Co-founder and Managing Director, BioImagene
India Pvt. Ltd. said, “Identifying
and nurturing young scientists and IT specialists
has been the key to our success. We understand
and recognize that our people often represent
the largest single area of investment.” Honing
the technical skills of our employees by providing
them with need and technology based training
programs, and organizing soft skills sessions
to maintain their high moral is also one of our
key success factors. Working onsite alongside
our clients gives our guys a better understanding
of our customer perception to deliver well designed
and well-thought productized solutions and services.
Today I am proud and I am sure so are my people
to be part of the BioImagene family, Abhijeet
further added.
Working on the similar theme to
support their business growth through customized
solutions and services, to connect life science
research with evolving IT, and take their innovations
across nations, BioImagene is scaling up their
software development infrastructure. The new state-of-the-art
facility of over 6000 sq.ft. can house close to
100 IT Professionals. This development center provides
100% uninterrupted power supply, broadband internet
connectivity, data storage and security, Smart
card based access control system, world class hardware
and software resources, IP based connectivity for
voice communications and other such facilities.
Speaking at the launch
an elated Mohan Uttarwar, Co-founder and CEO,
BioImagene Inc said, “We are extremely
happy to have the new facility of BioImagene
launched at the hands of Dr. Mashelkar and Padmashree
Lila Poonawalla. BioImagene is progressing tremendously,
after the acquisition of Scimagix Inc, late last
year, and plans to expand its offerings to all
the major Pharma, CROs and biotech companies
in the space of Tissue Image Analysis. With products
TissueMine, Cellmine & Proteinmine we are
well positioned for high throughput quantization
during Drug Efficacy studies, Preclinical Studies
and Animal ToxPath studies.”
Funded by prominent investors
and led by a strong management team, BioImagene
boasts of a stellar board of advisors consisting
of experts from the medical, pathology and imaging
technology fields. It has fostered close partnerships
with some of the leading organizations in the academic,
research and technology fields. In the future,
partnerships are going to become even more important
to BioImagene as it seeks companies to realize
the full commercial value of its discovery and
development potential. The company also intends
to strengthen the IP portfolio by way of patents
and research publications through its collaboration
with Ohio State University, Columbus, Ohio |